A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma

J Immunother Emphasis Tumor Immunol. 1995 Jul;18(1):52-6. doi: 10.1097/00002371-199507000-00007.

Authors

G R Weiss¹, K A Margolin, M Sznol, M B Atkins, L Oleksowicz, R Isaacs, J A Sosman, J H Doroshow, E G Trehu, J P Dutcher, et al.

Affiliation

¹ University of Texas Health Science Center at San Antonio, Division of Medical Oncology 78284-7884, USA.

PMID: 8535571
DOI: 10.1097/00002371-199507000-00007

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Carcinoma, Renal Cell / complications
Carcinoma, Renal Cell / therapy*
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Interleukin-6 / administration & dosage*
Interleukin-6 / adverse effects
Interleukin-6 / therapeutic use*
Kidney Neoplasms / complications
Kidney Neoplasms / therapy*
Lung Neoplasms / secondary
Lung Neoplasms / therapy
Lymphatic Metastasis
Male
Middle Aged
Soft Tissue Neoplasms / secondary
Soft Tissue Neoplasms / therapy

Substances

Interleukin-6